多发性硬化症患者接受β-干扰素治疗前6个月的生活质量。

Quality of life during the first 6 months of interferon-beta treatment in patients with MS.

作者信息

Arnoldus J H, Killestein J, Pfennings L E, Jelles B, Uitdehaag B M, Polman C H

机构信息

Department of Neurology, University Hospital Vrije Universiteit, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.

出版信息

Mult Scler. 2000 Oct;6(5):338-42. doi: 10.1177/135245850000600508.

DOI:10.1177/135245850000600508

PMID:11064444

Abstract

OBJECTIVES

To determine the quality of life (QoL) of MS patients during the initial 6 months of treatment with interferon-beta (IFN-beta). Furthermore, to determine whether changes in QoL relate to disability, emotional state, therapeutic expectations or side effect profile.

BACKGROUND

IFN-beta has been shown to have beneficial effects on the course of MS. Since the aim of IFN-beta treatment is not to cure but to slow down the disease it is important to know how this treatment affects QoL. Surprisingly, the impact of treatment with IFN-beta on QoL measures has not been extensively studied so far.

METHODS

Case report documentation, including EDSS, SF-36 and MADRAS scores, of 51 relapsing-remitting MS patients treated with IFN-beta was obtained at baseline and at months 1, 3 and 6. Patients also filled in a form about their expectations of therapy and a questionnaire on side effects.

RESULTS

During treatment there was a significant linear trend indicating improvement in the role-physical functioning (RPF) scale of the SF-36 (F(1,50)=4.9, P=0.032). A transient decrease at month 1 was found in the scale for bodily pain, indicating more experienced pain (F(1,50)=19.8, P<0.001). Subgroup analysis showed that patients with most depressive symptoms on the MADRAS at baseline contributed most to the increase in RPF scores over time (F(1,24)=5,6 P=0.026). Furthermore, we found associations between adverse event scores and several domains of QoL.

CONCLUSIONS

Our findings suggest that IFN-beta therapy has an impact on QoL of MS patients in that it improves role-physical functioning and transiently worsens experienced bodily pain. QoL during treatment with IFN-beta is influenced by depressive symptoms at baseline as well as by treatment-associated side-effects. Multiple Sclerosis (2000) 6 338 - 342

摘要

目的

确定使用β-干扰素（IFN-β）治疗的最初6个月内多发性硬化症（MS）患者的生活质量（QoL）。此外，确定生活质量的变化是否与残疾、情绪状态、治疗期望或副作用情况相关。

背景

已证明IFN-β对MS病程有有益影响。由于IFN-β治疗的目的不是治愈而是减缓疾病进展，了解这种治疗如何影响生活质量很重要。令人惊讶的是，迄今为止，IFN-β治疗对生活质量指标的影响尚未得到广泛研究。

方法

获取了51例接受IFN-β治疗的复发缓解型MS患者在基线时以及第1、3和6个月时的病例报告文件，包括扩展残疾状态量表（EDSS）、健康调查简表36（SF-36）和多发性硬化症抑郁量表（MADRAS）评分。患者还填写了一份关于其治疗期望的表格和一份关于副作用的问卷。

结果

治疗期间有显著的线性趋势，表明SF-36的身体功能角色（RPF）量表有所改善（F(1,50)=4.9，P=0.032）。在第1个月时发现身体疼痛量表有短暂下降，表明疼痛感受增加（F(1,50)=19.8，P<0.001）。亚组分析表明，基线时MADRAS上抑郁症状最严重（F(1,24)=5.6，P=0.026）的患者对RPF评分随时间的增加贡献最大。此外，我们发现不良事件评分与生活质量的几个领域之间存在关联。